Acute hospital care at home Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines hospital at home, the delivery of acute inpatient-level care in the patient home with clinical visits, remote monitoring and logistics support. It tests how far this model can grow from a Medicare waiver programme to a standard way of delivering acute care by 2034.

The policy position has settled. Congress extended the Medicare Acute Hospital Care at Home waiver as part of the Consolidated Appropriations Act, 2026, with the waiver running through September 2030, and by March 2026 366 programs across 139 health systems in 37 states had been approved. The conclusion is that health systems can plan multiyear investment in home-based acute care, which was not possible while the waiver was renewed in short extensions.

Large systems are moving from pilots to scale. Mass General Brigham reports nearly 10,000 patients treated since 2022 and a 70-bed capacity milestone, and plans to add oncology, postoperative care and behavioral health pathways in 2026. The conclusion is that the first adopters are widening diagnoses, which raises the share of admissions that can be treated at home.

Providers are consolidating around national platforms. DispatchHealth and Medically Home closed their merger in late May 2025 under the DispatchHealth name, and the combined company operates in more than 20 states. The conclusion is that health systems without their own logistics now have a national partner for the home visits, supplies and monitoring that the model needs.

The brief treats hospital at home as a high-impact signal with an eight year horizon to 2034. It identifies which systems and providers move first and what each means for health systems, payers and technology companies. It is a focused 101-page decision brief that presents an indicative trajectory rather than a segmented market model.

Hospital at home moves a patient who needs inpatient care out of the hospital bed and into the home. A care team visits, a clinician oversees the patient through video and connected devices, and supplies, tests and medicines arrive through a logistics service. The patient returns to the hospital if the condition worsens.

Medicare payment has carried the model since 2020. The waiver lets hospitals receive the same payment for acute care at home as for inpatient care in the facility, and the law now extends it through September 2030. The conclusion is that payment parity is secure for the planning period, and growth depends on operations rather than on policy.

Operations are scaling at health systems. Allegheny Health Network grew from about 7 to 8 admissions a month in January 2024 to about 40 by mid 2025, Cleveland Clinic launched across four Florida hospitals in April 2023 and treated roughly 1,000 patients in its first year, and a Mayo Clinic model developed with Kaiser Permanente is used by 21 health systems. The conclusion is that the model repeats from one system to the next, which lowers the risk of starting a programme.

The evidence supports wider use. Research cited in trade reporting puts the cost of home-based hospital care at roughly one-third below traditional inpatient care, with lower readmission rates and patient satisfaction more than 10 points above hospital benchmarks. The conclusion is that systems can use home beds to relieve capacity while holding quality, and payers have a reason to contract for them.

The limits are staffing, logistics cost, patient selection and the lack of commercial payer contracts outside Medicare. The brief tests each limit against the cost trajectory to 2034.

The hospital at home market, covering acute inpatient-level care delivered in the home by health systems and care-at-home providers, including clinical services, remote monitoring and logistics, and excluding routine home health, hospice, chronic disease remote monitoring and general telehealth, is valued at USD 3.0–5.0 billion in 2026 and is projected to reach USD 12.9–21.5 billion by 2034, at a CAGR of 20%.

The 2026 base rests on Medicare admissions at approved hospitals, together with the care-at-home services, remote monitoring and logistics that support them. Growth then follows the number of programmes, the diagnoses treated at home and commercial payer contracts.

The forecast is sensitive to staffing and logistics cost, commercial payer decisions and the pace at which systems add diagnoses.

Base case.

The base case assumes commercial payers follow Medicare over the period after 2028, bringing the inflection to about 2029 and a 2034 value near the middle of the range.

Accelerated case.

An accelerated case assumes strong outcome data and quick payer contracts, bringing the inflection to 2027 and lifting the 2034 value to the top of the range.

Delayed case.

A delayed case assumes high staffing cost and limited commercial coverage, moving the inflection to 2032 and holding growth at the bottom of the range.

Growth drivers

• Inpatient bed demand.
• Eligible acute admissions.
• Outcomes against inpatient care.
• Wider diagnoses.

Enablers

• Remote monitoring.
• Mobile diagnostics and logistics.
• Payment and registry evidence.
• Health system programmes.

Restraints and barriers

• Home environment suitability limits.
• Staffing and logistics capacity.
• Cost of staffing and logistics.
• Commercial payer coverage.

The direction of hospital at home is set by Medicare waiver policy, inpatient bed demand, remote monitoring advances, outcome evidence and the capacity of clinical staff and logistics.

The key participants in hospital at home include Mass General Brigham Incorporated, Mayo Clinic, Kaiser Foundation Health Plan, Inc., Cleveland Clinic, Highmark Health, Advocate Health, Inc., Christiana Care Health Services, Inc., The University of Chicago, University of Pennsylvania Health System, DispatchHealth, Masimo Corporation, Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., UnitedHealth Group Incorporated, Elevance Health, Inc., CVS Health Corporation, Humana Inc., Cigna Group, HCA Healthcare, Inc., Ascension Health Alliance, CommonSpirit Health, Providence St. Joseph Health, Intermountain Health, Sutter Health, Baxter International Inc., Becton, Dickinson and Company, Omnicell, Inc., Oracle Corporation, Epic Systems Corporation, the American Hospital Association, the Society of Hospital Medicine, the Centers for Medicare & Medicaid Services and the Medicare Payment Advisory Commission.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as commercial payers join Medicare.

Mass General Brigham, Mayo Clinic and Cleveland Clinic lead among health systems, DispatchHealth leads among care-at-home providers, and Masimo, Philips, Medtronic and GE HealthCare supply monitoring. Competitive intensity is moderate, with large systems building their own programmes and a few national providers serving the rest.

Where value migrates.

In 2026 value sits with health systems running Medicare programmes and with the monitoring and logistics services they buy. By 2029 it moves toward providers and systems that hold commercial payer contracts and treat a wider range of diagnoses. By 2034 it settles with hospital at home as a standard option, where staffing efficiency, outcome data and payer contracts carry the margin. Margins hold for programmes with scale and payer contracts, and narrow for small programmes without logistics.

The signals converge on a market where policy is settled and operations are the next limit. A waiver running to 2030, 366 approved programs and growing admissions at leading systems support growth, while staffing, logistics cost and commercial payer decisions hold back adoption.

Structural limits show where progress could slow: clinical staffing, home suitability, logistics cost and the pace of commercial contracts. The brief therefore tracks four indicators: admissions per programme, diagnoses treated at home, commercial payer contracts and readmission data.

Waiver extension first, then commercial payer contracts and wider diagnoses, then standard option status is the expected order of change.